Genzyme has done it before with Genzyme tissue repair and GZMO. A little different because of tracking company status which we don't exactly have. In theory Genz as a large corporate owner of GTCB stock could be forcing downward pressure on the stock by selling now to perhaps get a better deal for atryn or take over. Dew?
Market Data 
Markets 
AI
